Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Biospecimen and Clinical Data Study on Patients With Alzheimer's, Multiple Sclerosis, Parkinson's, and Huntington's, for Drug & Biomarker Discovery

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by Sanguine Biosciences
Sponsor:
Information provided by (Responsible Party):
Sanguine Biosciences
ClinicalTrials.gov Identifier:
NCT01592552
First received: November 16, 2011
Last updated: November 19, 2014
Last verified: November 2014
  Purpose

The purpose of this research project is to collect and store blood samples and clinical data. Researchers can then use the stored samples in future studies. Through such studies, they hope to find new ways to detect, treat, and maybe even prevent or cure health problems.


Condition
Alzheimer's Disease
Multiple Sclerosis
Parkinson's Disease
Huntington's Disease
Amyotrophic Lateral Sclerosis (ALS)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: A Multi-Center Longitudinal Biorepository Study to Provide Biospecimens & Clinical Data From Neurological Disease Patients To Approved Pre-Clinical And Clinical Investigators for Drug & Biomarker Studies

Resource links provided by NLM:


Further study details as provided by Sanguine Biosciences:

Primary Outcome Measures:
  • Biospecimens & Clinical Data collection from patients with neurological diseases. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    The purpose of this research project is to collect and store blood samples and clinical data. Researchers can then use the stored samples in future studies. Through such studies, they hope to find new ways to detect, treat, and maybe even prevent or cure health problems.


Estimated Enrollment: 600
Study Start Date: November 2011
Estimated Study Completion Date: November 2017
Estimated Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts
Neurological Condition
Collect blood and other biospecimens like saliva, urine and CSF for research purposes.
Control
Collect blood and other biospecimens like saliva, urine and CSF for research purposes.

Detailed Description:

Blood samples are collected in the comfort and safety of your home by a certified medical professional. We have mobile phlebotomists located in major metropolitan areas around the nation for your convenience.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

A diagnosis of Multiple Sclerosis, Alzheimer's, Huntington's, or Parkinson's Disease.

Criteria

Inclusion Criteria:

  • Males and females >18 to 100 years old
  • A diagnosis of neurological condition
  • Proof of diagnosis can be provided

Control group: Healthy donors, males and females, 18 to 100 years of age

Exclusion Criteria

  • Receipt of blood products within 30 days of study enrollment
  • Receipt of an investigational (unapproved) drug within 30 days of study enrollment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01592552

Contacts
Contact: Carlyn Crisostomo 877-864-3053 study@sanguinebio.com
Contact: Kristen Warren, MBS 877-864-3053 study@sanguinebio.com

Locations
United States, California
Sanguine Biosciences Recruiting
Los Angeles, California, United States, 91403
Contact: Carlyn Crisostomo    877-864-3053    donors@sanguinebio.com   
Principal Investigator: Carlyn Crisostomo         
Sponsors and Collaborators
Sanguine Biosciences
Investigators
Principal Investigator: Carlyn Crisostomo Sanguine Biosciences
  More Information

No publications provided

Responsible Party: Sanguine Biosciences
ClinicalTrials.gov Identifier: NCT01592552     History of Changes
Other Study ID Numbers: SAN-ND-01
Study First Received: November 16, 2011
Last Updated: November 19, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Sanguine Biosciences:
Alzheimer's Disease
Multiple Sclerosis
Parkinson's Disease
Huntington's Disease
Amyotrophic Lateral Sclerosis (ALS)

Additional relevant MeSH terms:
Alzheimer Disease
Amyotrophic Lateral Sclerosis
Huntington Disease
Motor Neuron Disease
Multiple Sclerosis
Parkinson Disease
Sclerosis
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Chorea
Cognition Disorders
Delirium, Dementia, Amnestic, Cognitive Disorders
Dementia
Demyelinating Autoimmune Diseases, CNS
Demyelinating Diseases
Dyskinesias
Genetic Diseases, Inborn
Heredodegenerative Disorders, Nervous System
Immune System Diseases
Mental Disorders
Metabolic Diseases
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Neuromuscular Diseases
Parkinsonian Disorders
Pathologic Processes

ClinicalTrials.gov processed this record on November 20, 2014